Compare · KEQU vs NTRA
KEQU vs NTRA
Side-by-side comparison of Kewaunee Scientific Corporation (KEQU) and Natera Inc. (NTRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- KEQU operates in Industrials, while NTRA operates in Health Care - the two are in different parts of the market.
- NTRA is the larger of the two at $56.36B, about 568.7x KEQU ($99.1M).
- NTRA has been more active in the news (25 items in the past 4 weeks vs 2 for KEQU).
- NTRA has more recent analyst coverage (25 ratings vs 0 for KEQU).
- Company
- Kewaunee Scientific Corporation
- Natera Inc.
- Price
- -
- -
- Market cap
- $99.1M
- $56.36B
- 1M return
- -
- -2.47%
- 1Y return
- -
- +95.51%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 2
- 25
- Recent ratings
- 0
- 25
Kewaunee Scientific Corporation
Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. It operates in two segments, Domestic and International. The company's products include steel, wood, laminate furniture, fume hoods, biological safety cabinets, laminar flow and ductless hoods, adaptable modular and column systems, moveable workstations and carts, epoxy resin worksurfaces, sinks, and accessories and related design services. Its laboratory products are used in chemistry, physics, biology, and other general science laboratories in the pharmaceutical, biotechnology, industrial, chemical, commercial, educational, government, and health care markets; technical products are used in facilities manufacturing computers and light electronics and by users of computer and networking furniture; and laminate caseworks that are used in educational, healthcare, and industrial applications. The company sells its products primarily through dealers, commissioned agents, and a national distributor, as well as through competitive bids submitted by the company and its subsidiaries in Singapore, India, and China. Kewaunee Scientific Corporation was founded in 1906 and is headquartered in Statesville, North Carolina.
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Latest KEQU
- Kewaunee Scientific Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure
- Kewaunee Scientific Announces Agreement to Acquire Nycom, Inc.
- SEC Form 10-Q filed by Kewaunee Scientific Corporation
- Kewaunee Scientific Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Kewaunee Scientific Reports Results for First Quarter of Fiscal Year 2027
- Kewaunee Scientific Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Kewaunee Scientific Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Kewaunee Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Kewaunee Scientific to Report Results for First Quarter Fiscal Year 2027
- SEC Form DEFA14A filed by Kewaunee Scientific Corporation
Latest NTRA
- EXECUTIVE CHAIRMAN Rabinowitz Matthew sold $299,214 worth of shares (748 units at $400.02) as part of a pre-agreed trading plan, decreasing direct ownership by 0.04% to 2,116,928 units (SEC Form 4) (for tax liability)
- CO-FOUNDER Sheena Jonathan sold $44,797 worth of shares (112 units at $399.97) as part of a pre-agreed trading plan, decreasing direct ownership by 0.05% to 217,574 units (SEC Form 4) to satisfy withholding obligation
- CEO AND PRESIDENT Chapman Steven Leonard sold $1,565,239 worth of shares (3,801 units at $411.80) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 87,431 units (SEC Form 4) to satisfy tax liability
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $1,400,994 worth of shares (3,419 units at $409.77) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 101,323 units (SEC Form 4) to satisfy withholding obligation
- SEC. AND CHIEF LEGAL OFFICER Rabinowitz Daniel sold $136,416 worth of shares (341 units at $400.05) as part of a pre-agreed trading plan, decreasing direct ownership by 0.20% to 167,880 units (SEC Form 4) to satisfy withholding tax
- CHIEF FINANCIAL OFFICER Brophy Michael Burkes sold $313,998 worth of shares (795 units at $394.97) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 45,779 units (SEC Form 4) to cover withholding tax
- PRESIDENT, CHIEF BUS. OFFICER Fesko John sold $120,804 worth of shares (302 units at $400.01) as part of a pre-agreed trading plan, decreasing direct ownership by 0.15% to 195,276 units (SEC Form 4) to cover withholding tax
- Signatera™ in Head and Neck Cancer: Three New Publications Demonstrate Strong Clinical Performance and Actionability
- Medicare Expands Coverage for Signatera™ MRD Test in Hepatocellular Carcinoma
- CHIEF FINANCIAL OFFICER Brophy Michael Burkes sold $1,313,470 worth of shares (3,084 units at $425.90) as part of a pre-agreed trading plan (SEC Form 4)